Commercial stage, focused on rare diseases w significant unmet needs. Endocrine franchise includes RECORLEV™, cortisol synthesis inhibitor in Ph 3 for endogenous Cushing's syndrome, and veldoreotide, next-gen somatostatin analog for acromegaly. Neuromuscular franchise includes KEVEYIS® approved for primary periodic paralysis. Company sold NA rights for MACRILEN™ to Novo Nordisk for $145 m upfront and tiered royalties in Oct 2018. RECORLEV Ph 3 data (LOGICS trial) exp end of Q1 2020; NDA submission exp Q3 2020.
Central Nervous System, Rare Disease
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by